According to the results of a systematic review and network meta-analysis reported in the BMJ, vaccination of older adults with an adjuvant recombinant subunit herpes zoster vaccine [Shingrix] is more effective for prevention of shingles than a live attenuated vaccine [Zostavax], but is also associated with a greater risk of injection site adverse reactions. …